Abstract
The effect of nasal corticosteroid therapy on allergic rhinitis is uncertain. In a double-blind, placebo-controlled study over 3 months, we investigated the influence of a new corticosteroid spray, fluticasone propionate aqueous nasal spray (FPANS), on Langerhans cells (CD1a+ cells), HLA-DR+ cells, and T cells in nasal mucosa. Efficacy was evaluated by nasal symptom score. This treatment significantly decreased the number of CD1a+ cells and HLA-DR+ cells in the nasal mucosa. Furthermore, a clear trend of decreasing numbers of T cells in nasal epithelium was found. No change in nasal symptom score was found after the treatment period. These findings suggest that fluticasone propionate aqueous nasal spray decreases the antigen presentation in nasal allergy.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intranasal
-
Adult
-
Androstadienes / administration & dosage
-
Androstadienes / pharmacology*
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / pharmacology*
-
Antigens, CD / biosynthesis
-
Double-Blind Method
-
Female
-
Fluticasone
-
Glucocorticoids
-
HLA-DR Antigens / biosynthesis
-
Humans
-
Langerhans Cells / drug effects*
-
Langerhans Cells / immunology
-
Male
-
Nasal Mucosa / cytology
-
Nasal Mucosa / drug effects*
-
Nasal Mucosa / immunology
-
Placebos
-
Rhinitis, Allergic, Perennial / drug therapy*
-
Rhinitis, Allergic, Perennial / immunology
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
Substances
-
Androstadienes
-
Anti-Inflammatory Agents
-
Antigens, CD
-
Glucocorticoids
-
HLA-DR Antigens
-
Placebos
-
Fluticasone